Issues‎ > ‎vol19n1‎ > ‎

Protective Effects of Exogenous Melatonin on Cisplatin- Induced Acute Nephrotoxicity in Rats

Kochar Idrees Mahmood & Sardar Mirza Kadir

Department of General Science, College of Basic Education, Charmo University, Chamchamal, Sulaimani, Kurdistan Region –Iraq
Department of Biology, School of Sciences, University of Sulaimani, Sulaimani, Kurdistan Region –Iraq



This study was planned to investigate the consequences of exogenous administration of
melatonin on the amelioration of some biochemical variables in cisplatin (CP)-induced
acute nephrotoxicity in rats. Twenty-four male rats weighing 300-350g were used.
Housing of the animals and the experiment were achieved and the rats were -housed in
the Department of Biology /College of Science/ Sulaimani University. The Animals were
divided into three groups (n=5); control group (receiving prepared standard chow for rats
and water ad libitum); model group(The animals administered a single intraperitoneal
(i.p) dose of CP (8 mg/kg BW.); and the third group in addition to CP injection the
animals were supplemented with melatonin (180 mg/kg food) at the same day of CP-
injection for five days. Finally, the blood specimen was taken using cardiac puncture.
The studied parameters include Malondialdehyde (MDA), serum creatinine, serum urea,
serum total bilirubin, serum albumin, serum electrolytes (Ca+2, Na+ and K+), as well as
some hematological parameters (WBC, RBC, HCT, HGB). Our results showed
significant (P<0.05) elevation in the serum level of MDA,, creatinine, urea and total
bilirubin in model group. On the other hand, the WBC count was also increased
significantly (P<0.01), whereas there was no significant alterations in the level of
calcium, sodium, and potassium. The outcome of our study indicated that the melatonin
administration in injected rats for five days significantly (P<0.01) improved the elevated
serum levels of MDA, creatinine, urea, total bilirubin and WBC count. In conclusion,
this study confirmed that melatonin has protective effects of ameliorating the
nephrotoxicity induced by cisplatin in rat.

Key Words:


[1] Luo, J., et al., "The molecular mechanisms of the attenuation of cisplatin-induced acute renal failure by N-acetylcysteine in rats". Nephrology Dialysis Transplantation, Vol. 23, No. 7, pp. 2198-2205. (2008).

[2] Kawai, Y. and M. Gemba. "Cisplatin-induced renal injury in LLC-PK1 cells. in Proceedings of the 6th World Congress on Alternatives and Animal Use in the Life Sciences". 2007.

[3] Mohan, I.K., et al., "Protection against cisplatin-induced nephrotoxicity by Spirulina in rats". Cancer chemotherapy and pharmacology, Vol 56, No. 6, pp. 802-808.(2006).

[4] Sohaib, M., et al., "Assessing tubular damage due to Cisplatin Nephrotoxicity, using Tc-99m MAG3". World Journal of Nuclear Medicine, Vol 4. No. 2, pp 99. (2005).

[5] Gonzalez, V.M., et al., "Is cisplatin-induced cell death always produced by apoptosis?" Molecular pharmacology, Vol. 59, No. 4, pp. 657-663. (2001).

[6] Takahara, P.M., C.A. Frederick, and S.J. Lippard, "Crystal structure of the anticancer drug cisplatin bound to duplex DNA". Journal of the American Chemical Society, Vol. 118, No. 49, pp. 12309-12321. (1996).

[7] Turchi, J.J., "Nitric oxide and cisplatin resistance: NO easy answers". Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 12, pp. 4337-4338.(2006).

[8] Anisimov, V.N., et al., "Melatonin as antioxidant, geroprotector and anticarcinogen". Biochimica et Biophysica Acta (BBA)-Bioenergetics, Vol. 1757, No. 5, pp. 573-589. (2006).

[9] Carrillo-Vico, A., et al., "Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance". The FASEB Journal, Vol. 18, No. 3, pp. 537-539.(2004).

[10] Okatani, Y., et al., "Protective effect of melatonin against mitochondrial injury induced by ischemia and reperfusion of rat liver". European journal of pharmacology, Vol. 469, No. 1, pp. 145-152.(2003).

[11] Drijfhout, W.J., "Melatonin on-line: development of trans pineal microdialysis and its application in pharmacological and chronobiological studies". 1996, University of Groningen.

[12] Pandi‐Perumal, S.R., et al., "Melatonin". Febs Journal, Vol. 273, No. 13, pp. 2813-2838.(2006).

[13] Reiter, R.J., et al., "Actions of melatonin in the reduction of oxidative stress". Journal of biomedical science, Vol. 7, No. 6, pp. 444-458.(2000).

[14] Reiter, R.J., et al., "Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans". ACTA BIOCHIMICA POLONICA-ENGLISH EDITION, Vol. 50, No. 4, pp. 1129-1146. (2003).

[15] Ateşşahin, A., et al., "Chemoprotective effect of melatonin against cisplatininduced testicular toxicity in rats". Journal of pineal research, Vol. 41, No. 1, pp. 21-27.(2006).

[16] Raja, G., et al., "Repeated bouts of high-intensity exercise and muscle glycogen sparing in the rat". Journal of experimental biology, Vol. 206, No. 13, pp. 2159-2166. (2003).

[17] Markova, M., et al., "Effect of Low-dose Chronic Melatonin Administration on Metabolic and Hormonal Variables of Young Laboratory Rats". Acta Veterinaria Brno, Vol. 73, No. 4, pp. 445-453.(2004).

[18] Lopez‐Gonzalez, M.A., et al., "Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants". Journal of pineal research, Vol. 28, No. 2, pp. 73-80. (2000).

[19] Weinstein, T., et al., "Haemolysis in haemodialysis patients: evidence for impaired defence mechanisms against oxidative stress". Nephrology Dialysis Transplantation, Vol. 15, No. 6, pp. 883-887.(2000).

[20] Yao, X., et al., "Cisplatin nephrotoxicity: a review". The American journal of the medical sciences, Vol. 334, No 2. pp. 115-124.(2007).

[21] Gopal, N., A. Selvam, and P. Muddegowda, "Serum Gamma Glutamyl Transferase levels in Obese South Indian adults with reference to atherogenic lipid risk factors and lipid peroxides". International Journal of Medical and Health Sciences, Vol. 1, pp. 35-42. (2012).

[22] Pan, H., et al., "Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/ nitrosative stress, inflammation, and cell death". Journal of Pharmacology and Experimental Therapeutics, Vol. 328, No. 3, pp. 708-714.(2009).

[23] Kücükakin, B., et al., "Oxidative stress in relation to surgery: is there a role for the antioxidant melatonin?" Journal of Surgical Research, Vol. 152, No. 2, pp. 338-347. (2009).

[24] Montilla-López, P., et al., "Comparison of melatonin versus vitamin C on oxidative stress and antioxidant enzyme activity in Alzheimer's disease induced by okadaic acid in neuroblastoma cells". European journal of pharmacology, Vol. 451, No. 3, pp. 237-243.(2002).

[25] Erdinç, M., et al., "The effects of nifedipine on renal perfusion pressure and kidney during cisplatin-induced nephrotoxicity in rats". Dicle Tıp Dergisi, Vol. 34, No. 4, pp. 248-253.(2007).

[26] Hara, M., et al., "Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatininduced nephrotoxicity in rats". Journal of pineal research,Vol. 30, No. 3, pp. 129-138. (2001).

[27] Ali, B., et al. "Amelioration of cisplatin-induced nephrotoxicity in rats by tetramethylpyrazine, a major constituent of the Chinese herb Ligusticum wallichi". Experimental biology and medicine, Vol. 233, No. 7, pp. 891-896. (2008).

[28] Kim, Y.O., et al. "Serum albumin level correlates with disease severity in patients with hemorrhagic fever with renal syndrome". Journal of Korean medical science, Vol. 18, No. 5. pp. 696-700. (2003).

[29] Fukutomi, J., et al., "Scavenging activity of indole compounds against cisplatin-induced reactive oxygen species". Life sciences, Vol. 80, No. 3, pp. 254-257. (2006).

[30] Kyotani, S., et al., "A study of cis-dianminedichloroplatinum (II) suppositories for the treatment of rabbit uterine endometrial carcinoma [J]". Bio Pharm Bull, Vol. 16, pp. 55-58. (1993).

[31] Potkul, R.K., et al., "Toxicities in rats with free versus liposomal encapsulated cisplatin". American journal of obstetrics and gynecology, Vol. 164, No.2, pp. 652-658. (1991).

[32] Von Hoff, D., et al. "Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer treatment reports, Vol. 63, No. (9-10), pp. 1527. (1979).

[33] Dominguez, M.F., et al., "Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors". Journal of Pharmacology and Experimental Therapeutics, Vol. 297, No. 3, pp. 1106-1112. (2001).

[34] Viswanathan, V., et al., Serum albumin levels in different stages of type 2 diabetic nephropathy patients. Indian J Nephrol, Vol. 14, pp. 89-92. (2004).

[35] Blom, J., K. Kurth, and T. Splinter, "Renal function, serum calcium and magnesium during treatment of advanced bladder carcinoma with cis-dichlorodiamineplatinum: Impact of tumour site, patient age and magnesium suppletion". International urology and nephrology, Vol. 17, No.4, pp. 331-339. (1985).

[36] Lishner, M., et al., "Hypercalcaemia-induced acute renal failure as a presenting feature of T-cell leukaemia". European journal of pediatrics, Vol.146, No. 1, pp. 68-69. (2007).

[37] Abdelghani, L., et al., "Sodium-wasting nephropathy caused by cisplatin in esophageal cancer". The journal of supportive oncology, Vol. 6, No. 7, pp. 305. (2008).

[38] Sheena, N., T. Ajith, and K. Janardhanan, "Prevention of nephrotoxicity induced by the anticancer drug cisplatin, using". Current Science, Vol. 85, No. 4. (2003).

[39] Glover, P. "Hypokalaemia". Critical Care and Resuscitation, Vol. 1, No. 3, pp. 239. (1999).

[40] Nakou, K., et al., "Low normal potassium levels in acute renal failure: Evidence of leptospirosis". Infection, Vol. 28, No. 3, pp. 196-196. (2000).

[41] Hörl, W.H., "Adjunctive therapy in anaemia management". Nephrology Dialysis Transplantation, Vol. 17 (suppl 5). pp. 56-59. (2002).

[42] Eschbach, J.W., et al. "Treatment of the anemia of progressive renal failure with recombinant human erythropoietin". New England Journal of Medicine, Vol. 321, No. 3, pp. 158-163. (1989).

[43] Nowrousian, M. and C. Schmidt, "Effects of cisplatin on different haemopoietic progenitor cells in mice". British journal of cancer, Vol. 46, No. 3, pp. 397-402. (1982).

[44] Yamate, J., et al., "Participation of different macrophage populations and myofibroblastic cells in chronically developed renal interstitial fibrosis after cisplatin-induced renal injury in rats". Veterinary Pathology Online, Vol. 39, No. 3, pp. 322-333. (2002).

[45] Zhang, B., et al., "Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-α produced by renal parenchymal cells". Kidney international, Vol. 72, No. 1, pp. 37-44. (2007).

[46] Reiter, R.J., et al. "When melatonin gets on your nerves: its beneficial actions in experimental models of stroke". Experimental biology and medicine, Vol. 230, No. 2, pp. 104-117. (2005).

[47] Darwish, D.F. "Effect of Exogenous Melatonin on Some Haematological and Biochemical Parameters in Induced-Thyrotoxic and Hypothyroid Male Albino Rats". (MSc.thesis), (2007).

[48] Naghizadeh,B.; Boroushaki,M.T., Mashhadian,N.V., Mansouri,S.M.T., "Protective Effects of Crocin     against Cisplatin-Induced Acute Renal Failure and Oxidative Stress in Rats". Iran.Biomed. J. Vol. 12, No. 2, pp. 93-100. (2008).

[49] Awadallah, A. M.; Moussa, F.I.; Abd El Hameed, N. "Treatment of cisplatin haematotxicity with lasix or selenium or both in adult male rabbits". Pakistan journal of biological science Vol. 4, No. 1, pp. 89- 93. (2001).

[50] Zietse, R., "Renal physiology and pathology: An Introduction. EJHP practice" Vol. 12, No. 2, pp 44-45, (2006).